News|Articles|February 15, 2025
The Weekly Roundup: February 10-14
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Rezpegaldesleukin targets the IL-2 receptor complex and has received Fast Track Designation for moderate to severe atopic dermatitis.
- Personalized atopic dermatitis treatment focuses on individualized care and building trust with patients and caregivers.
In case you missed it, this week we had news about rezpegaldesleukin’s fast track designation for AD, bimekizumab’s long-term efficacy for HS, conference recaps of SBS and MOPD, and more.
Advertisement
To stay up-to-date with the latest dermatology news, sign up to receive our
Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex.
Tina Bhutani-Jacques, MD, highlighted the importance of individualized and informative care while building trust among patients and caregivers.
Review emerging therapies for vitiligo, melasma, PIH, and albinism, including topical, systemic, light-based, and laser treatments.
The top videos under the hashtag, #spironolactone” had low scores on the mDISCERN and GQS scales, according to Adam Friedman, MD, FAAD, senior author of the study.
A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.
Botox Cosmetic has evolved from its accidental discovery to a leading treatment in dermatology, balancing medical innovation with ethical considerations.
Dobkin underwent the procedure in order to connect with his patients considering it for themselves.
Recent technological advancements such as the development and use of human cellular and tissue-based products and advanced skin substitutes have transformed limb preservation.
Catch up on coverage from the 2025 South Beach Symposium held in Miami Beach, Florida.
Lisa Weiss, MMSc, PA-C, and colleagues offered insights on managing severe atopic dermatitis cases with biologics, nonsteroidal treatments, and strategies for addressing physical and emotional impacts.
This review of the latest dermatologic studies includes insights into endocrine, psychological, and nutritional aspects in women with hidradenitis suppurativa; forms of hair loss among individuals with anxiety disorder; and more.
Each treatment saw very mild clinical and dermatologic responses with low levels of patient satisfaction.
New drugs targeting IL-4, IL-13, and IL-31 pathways provide options for tailored eczema treatments.
At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, presented a case of a woman aged 27 years who had eczematous lesions covering more than 20% of her BSA.
Trauma-induced melanocyte implantation can lead to subcutaneous melanoma, mimicking melanoma of unknown primary but with distinct diagnostic criteria.
Catch up on coverage from the 2025 Masters of Pediatric Dermatology held in Miami Beach, Florida.
Uniting all professions should be the goal as it concerns the patient and the access to care.
Clinicians observed a positive relationship between scalp hair regrowth and downstream treatment benefits for patients with alopecia areata.
Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.
Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.
Are you attending Winter Clinical Hawaii? Answer our poll below to let us know.
Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.
The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.
Explore 2025’s dermatology M&A trends, economic shifts, and key investment drivers shaping the industry's future.
Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.
Key 2025 tax law changes for dermatologists include expiring TCJA provisions, potential rate adjustments, and new deduction policies under Trump.
Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.
Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.
Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.
Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.
A global review found that skin condition advocacy groups offer diverse mental health resources, but accessibility gaps persist worldwide.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5
